Moderna, Inc.
$218.08
+3.91 · +1.83% today
Market open · updated 12:45:29 PM ET
- High
- $217.25 11:05 AM
- Low
- $202.90 7:25 AM
Against the S&P 500 Price change through Oct 27, 2026
MRNA+605.22%
S&P 500+12.87%
MRNA+680.08%
S&P 500+12.32%
MRNA+189.21%
S&P 500+87.41%
MRNA−38.99%
S&P 500+69.55%
Key numbers
- Previous close
- $214.17
- Open
- $216.26
- Day's range
- $215.38 – $224.96
- 52-week range
- $22.28 – $254.48
- Volume
- 6.3 million
- Average volume
- 17.2 million
- Market value
- $87.1 billion
- Earnings per share
- -$7.96last 12 months
- Beta
- 0.90moves about as much as the market
- Dividend
- None
- 50-day average
- $179.75
- 200-day average
- $84.76
Friday, Nov 6, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who Moderna competes with From our value chain
Moderna in the news
- HeadlineModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher24/7 Wall Street · October 28, 2026 at 12:04 PM ET
- HeadlineAxsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityThe Motley Fool · October 28, 2026 at 9:24 AM ET
- HeadlineMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?MarketBeat · October 27, 2026 at 10:20 AM ET
- HeadlineModerna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.Barrons · October 27, 2026 at 9:00 AM ET
- HeadlineThe excitement around Moderna's cancer vaccine is cooling. Here's why.Market Watch · October 26, 2026 at 9:50 AM ET
- HeadlineModerna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady24/7 Wall Street · October 26, 2026 at 9:14 AM ET
- Pre-market reportPre-Market Report: Futures Rise as Earnings-Heavy Week BeginsWiseView Research desk · October 26, 2026
- HeadlineModerna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy TranscriptSeeking Alpha · October 24, 2026 at 6:57 PM ET
Earnings
Next report: Friday, Nov 6, 2026, before the open.
Congress trades in MRNA
4 purchases and 3 sales in the latest 7 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 11, 2026 | Oct 9, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Aug 26, 2025 | Sep 12, 2025 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Jul 25, 2025 | Aug 8, 2025 |
| Rob BresnahanHouse | Sale | $1,001 - $15,000 | Apr 8, 2025 | May 8, 2025 |
| Rob BresnahanHouse | Purchase | $1,001 - $15,000 | Feb 25, 2025 | Mar 28, 2025 |
| Julie JohnsonHouse · D-Texas | Sale | $1,001 - $15,000 | Jan 15, 2025 | Feb 13, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,700
- Headquarters
- Cambridge, Massachusetts
- Website
- modernatx.com
- Listed
- Dec 7, 2018
More biotechnology stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.